[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Ca Cancer J Clin, 2016, 66: 115-132.
[2] Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med, 2014, 11: e1001624.
[3] Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A Meta-analysis. Gastroenterology, 2018, 154: 1706-1718.
[4] Lee SS, Sherman M. Why won't the alpha-fetoprotein test go gentle into the good night. Gastroenterology, 2018, 154: 1572-1573.
[5] Yao M, Zhao J, Lu F. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. Oncotarget, 2016, 7: 3702-3708.
[6] 原发性肝癌诊疗规范(2017年版). 临床肝胆病杂志, 2017, 33: 1419-1431.
[7] Mcmahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med, 2001, 135: 759-768.
[8] Galle PR,Forner A,Llovet JM,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018, 69: 182-236.
[9] 闫晓彤, 姚明解, 关贵文, 等. 抗病毒治疗对AFP在慢性乙肝相关肝癌诊断应用中的影响. 郑州大学学报(医学版), 2018,53:19-22. |
